Successful Desensitization for Hydroxychloroquine Anaphylaxis

Donado, Carmen Díaz; Díez, Elena Maquiera

doi:10.3899/jrheum.091453

Cited by 18 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…- Successful desensitization protocols to HCQ CADR (1 case for HCQ anaphylaxis) were reported with a daily dose of 0.1-400 mg/ml which was gradually increased during 36 days [6,52,53]; 1 case of systemic anaphylactic reaction with shock due to Qu was observed [54]. …”

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

Background: Currently used antimalarial drugs (AM) are hydroxychloroquine and chloroquine, which are prescribed for many autoimmune disorders. The value of skin tests on cutaneous adverse drug reactions (CADR) with AM remains unknown. Objective: The main objective of this retrospective study is to know whether skin tests for AM are useful and how to manage the recovery of AM therapy in these patients. Methods: All patients referred for suspected CADR secondary to AM between 2001 and 2014 in eight French dermatology centers were retrospectively reviewed. Results: We report herein a retrospective series of 20 patients with CADR and AM involvement. Skin tests, performed in 14/20 patients, were negative in all cases. Six patients had an oral provocation test with recurrence of CADR in 1 case. Conclusion: We encourage dermatologists to perform oral provocation tests in nonsevere CADR in order to allow AM rechallenge at progressive doses.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In cases of immediate reactions, Soria et al [34] performed prick-tests with the undiluted drug with negative results. In case of anaphylaxis, dilution up to 1/10,000 has been advised [40].…”

Section: Dhrmentioning

confidence: 99%

Treating COVID-19: Review of Drug Hypersensitivity Reactions

Dordal¹,

Regás²,

Martí-Garrido³

et al. 2020

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…in 2006 reported desensitization to HCQ in 36 days in four adult patients with SLE or rheumatoid arthritis. Díaz Donado and Maquiera Díez in 2010 reported a desensitization to HCQ in 28 days in a 48‐yr‐old man with SLE and HCQ anaphylaxis. Due to the severe and poor controlled SLE in our patient, these previously described procedures with a 4 to 5 wk length were considered too long, and therefore, a shorter schedule with a cluster up dosing on the first 3 days was designed.…”

Section: Desensitization Schedulementioning

confidence: 99%